Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02736227 · ClinicalTrials.gov registry record · NA
Biomarkers Predicting Successful Tacrolimus Withdrawal and Everolimus (Zortress) Monotherapy Early After Liver Transplantation
A NA study, sponsored by Northwestern University.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT02736227 is a NA study that has completed, run by Northwestern University. The registered enrollment target is 28 participants.
The verdict
NCT02736227, a NA study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
Most patients who get a liver transplant must take immunosuppressants for the rest of their lives. However, this has occurred at the expense of chronic CNI toxicity, e.g. chronic kidney disease (CKD), metabolic complications, infections and malignancy. Everolimus (EVL) is a drug that may stabilize or improve kidney function for patients with chronic kidney disease (CKD) that has been caused by immunosuppressants. EVL is used for standard of care treatment to prevent transplant liver rejection in combination with other immunosuppressants, such as tacrolimus. The overall aim of this study is to examine a combination of two different immunosuppressants and EVL to determine if patients may have stabilized and/or improved kidney function without liver rejection. This study will look at how safe it is to slowly withdraw one anti-rejection medication while continuing to take the other medicine, and whether this can be done without liver rejection occurrence.
Interventions
- DRUG Tacrolimus Withdrawal and Everolimus Monotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-03 |
| Est. Completion | 2021-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02736227
The ClinicalTrials.gov registry entry for NCT02736227 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tacrolimus Withdrawal and Everolimus Monotherapy is the first listed.
NCT02736227 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02736227 about?
NCT02736227 is a clinical study titled "Biomarkers Predicting Successful Tacrolimus Withdrawal and Everolimus (Zortress) Monotherapy Early After Liver Transplantation". Most patients who get a liver transplant must take immunosuppressants for the rest of their lives. However, this has occurred at the expense of chronic CNI toxicity, e.g. chronic kidney disease (CKD), metabolic complications, infections and malignancy. Everolimus (EVL) is a drug that may stabilize o...
What is the current status of trial NCT02736227?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2016-03. Estimated completion is 2021-03.
What interventions are being tested in trial NCT02736227?
The interventions under investigation include: Tacrolimus Withdrawal and Everolimus Monotherapy (DRUG).
Who is sponsoring clinical trial NCT02736227?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.